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Sanford D. Markowitz,4,6,8 and Georgia L. Wiesner3,4,6,7
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Americans and is the second leading cause of cancer mortality.
Only aminority (~5%) of familial CRC can be explained by known genetic variants. To identify susceptibility genes for familial colorectal
neoplasia, the colon neoplasia sibling study conducted a comprehensive, genome-wide linkage scan of 194 kindreds. Clinical informa-
tion (histopathology, size and number of polyps, and other primary cancers) was used in conjunction with age at onset and family
history for classiﬁcation of the families into ﬁve phenotypic subgroups (severe histopathology, oligopolyposis, young, colon/breast,
and multiple cancer) prior to analysis. By expanding the traditional affected-sib-pair design to include unaffected and discordant sib
pairs, analytical power and robustness to type I error were increased. Sib-pair linkage statistics and Haseman-Elston regression identiﬁed
19 linkage peaks, with interesting results for chromosomes 1p31.1, 15q14-q22, 17p13.3, and 21. At marker D1S1665 (1p31.1), there was
strong evidence for linkage in the multiple-cancer subgroup (p¼ 0.00007). For chromosome 15q14-q22, a linkage peak was identiﬁed in
the full-sample (p¼ 0.018), oligopolyposis (p¼ 0.003), and young (p¼ 0.0009) phenotypes. This region includes theHMPS/CRAC1 locus
associated with hereditary mixed polyposis syndrome (HMPS) in families of Ashkenazi descent.We provide compelling evidence linking
this region in families of European descent with oligopolyposis and/or young age at onset (%51) phenotypes. We found linkage to
BRCA2 in the colon/breast phenotypic subgroup and identiﬁed a second locus in the region of D21S1437 segregating with, but distinct
from, BRCA2. Linkage to 17p13.3 at marker D17S1308 in the breast/colon subgroup identiﬁed HIC1 as a candidate gene. We demon-
strated that using clinical information, unaffected siblings, and family history can increase the analytical power of a linkage study.Introduction
Of the 145,290 CRC cancer cases diagnosed every year in
the United States, 20%–25% have a family history of colon
cancer.1 Studies have shown that the risk for CRC in ﬁrst-
degree relatives (FDR) of patients with either CRC or ade-
nomatous polyps is 2- to 4-fold greater than that for the
general population.2 Studies with twins suggest that up
to 35% of CRC is genetic,3 whereas only a small minority
(2%–6%) of familial CRC cases can be explained by known
genetic variants.4,5 To identify susceptibility genes for fa-
milial colorectal neoplasia, we located and recruited into
our colon neoplasia sibling study (CNSS) kindreds demon-
strating familial clustering of colon cancers and colon
adenomas and polyps.
Colon neoplasia is a heterogeneous disease both in its
genetic (allelic and locus) origins and in phenotypic pre-
sentation and thus offers signiﬁcant challenges both in de-
signing and in analyzing a linkage study. Frequently, all
families with affected individuals (CRC or colon neoplasia)
are analyzed together, the rationale being that increasing
sample size also increases the analytical power. This is
correct and appropriate in the absence of genetic hetero-
geneity. However, in the presence of such heterogeneity,
pooling families with diverse phenotypic expression of
disease may actually serve to increase genetic heterogene-ity, with a resulting loss in analytical power. Therefore,
we hypothesized that clinical information and family his-
tory could be used to identify families with both similar
phenotypes and genetic homogeneity, hence increasing
analytical power.We stratiﬁed the complete set of 194 fam-
ilies, which had fulﬁlled our criteria for inclusion in this
study, into ﬁve phenotypic subgroups (severe histopathol-
ogy, oligopolyposis, young, colon/breast, and multiple
cancer) prior to performing any statistical analysis. Classi-
ﬁcation of phenotypic subgroups was not exclusive, and
families were classiﬁed into more than one phenotypic
subgroup.
In addition to the classiﬁcation and implementation of
innovative phenotypes, we expanded upon the traditional
affected-sib-pair design by incorporating both concordant
and discordant sib pairs into the analysis. The CNNS study
recruits all siblings (affected and unaffected) as well as
parents. Traditionally, in affected-sib-pair designs, infor-
mation from unaffected siblings is used only to help de-
termine identity by descent (IBD) allele sharing when
the parental marker genotypes are incompletely known;
thus, phenotypic information that could be used to in-
crease the robustness and analytical power of the study is
discarded.6 An analysis that is based only on affected sib
pairs can result in incorrect inferences about linkage be-
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does not include an appropriate control group of discor-
dant sibs.6 Regions of the genomemay demonstrate excess
allele sharing among all types of sibling pairs, and these
observations are better explained by transmission distor-
tion and relative ﬁtness.6–8 Matched-sibling controls pro-
vide protection against these problems, making the test
statistics more robust to type I error.6 Our objective was
to use not only the information from unaffected individ-
uals but also speciﬁc phenotype deﬁnitions to lessen
genetic heterogeneity, thereby increasing analytical power
in our search for CRC susceptibility genes.
Severe histopathology was our primary analysis pheno-
type used in our previous study identifying chromosome
9q22.2-31.2 as harboring a susceptibility gene for familial
colon neoplasia.9 Evidence for linkage to this region has
been conﬁrmed in two other studies of familial colorectal
cancer and is designated as Colorectal Cancer Susceptibil-
ity 1 (CRCS1; MIM 608812).10,11 Here, we report complete
results for all the phenotypic subgroups and, in particular,
strong evidence for linkage to chromosome 1 for kindreds
with multiple cancers.
Subjects and Methods
Ascertainment and Collection of Familial Colorectal
Neoplasia Kindreds
Kindreds were enrolled in the CNSS, after review and approval of
the study design and of all informed-consent documents by the
Institutional Review Board of University Hospitals of Cleveland.
Initial ascertainment was nationwide as previously described9
and includes kindreds of European American (91%), Jewish Amer-
ican (7%), and African American (2%) descent: We enrolled fami-
lies (1) if at least one sibling was affected with colorectal cancer, or
had adenomatous polyps, at or before the age of 65 and (2) if there
was a second living sibling who was willing to participate. From
that sample, we selected for inclusion in this study 200 kindreds
that met the following criteria: (1) the presence of an index case
and a full sibling both of whom had been diagnosed with colorec-
tal cancer, or with colon adenomatous polyps, by age 65 years; (2)
histological veriﬁcation of colonic adenomatous polyps or colorec-
tal cancer; (3) no histological evidence for inﬂammatory-bowel
disease; (4) no evidence of known hereditary forms of colorectal
cancer (e.g., familial adenomatous polyposis (FAP [MIM 175100])
and hereditary nonpolyposis colorectal cancer (HNPCC [MIM
124035, 124036, 60078, 609309, 600259, 609310, and
609395])), which were excluded from this analysis by a combina-
tion of pedigree review and molecular testing, as previously de-
scribed;9 and (5) donation of a blood sample for genetic analysis
from two or more affected siblings. In addition, we requested
blood samples from all parents and siblings who were available
and willing to participate in the study.
Individuals of any age, who had undergone an endoscopic
colon examination with no ﬁnding of either colon cancer or ade-
nomas, were classiﬁed as unaffected—this criterion was used for
determining unaffected status for all phenotypic subgroups unless
otherwise indicated. We note that having a negative colon endos-
copy places an individual at low risk of developing colon cancer or
advanced colon adenomas for 5 to 10 years subsequent to the
negative examination.12–14724 The American Journal of Human Genetics 82, 723–736, March 2Families were checked for pedigree and genotyping errors with
the RELTEST and MARKERINFO programs in the S.A.G.E.15 pack-
age.9,15 As a result, six families were eliminated from the analysis
for incorrectly speciﬁed relationships: In four cases, the affected
pairs were most probably half siblings, and in two families, the
affected pairs were monozygotic (MZ) twins. Ultimately, there
were 194 families available (complete set) for analysis.
Phenotypic Subgroups
In recognition of the heterogeneous nature of colon neoplasia, we
utilized clinical information to stratify the complete set of 194
kindreds into ﬁve clinical subgroups (severe histopathology,
oligopolyposis, young, colon/breast, and multiple cancer) prior
to performing any statistical analysis. Detailed deﬁnitions of these
phenotypes are given in Table 1. Because of the Ashkenazi-speciﬁc
I1307K variant in the APC gene,16 all kindreds with Ashkenazi
Jewish heritage were tested and excluded from the analysis if the
results were positive.9 However, it is speculated that there may
be further Ashkenazi-speciﬁcmutations17,18 in the remaining fam-
ilies of Jewish descent in the complete (n¼ 13), young (n¼ 4), and
oligopolyposis subgroups (n ¼ 3); sensitivity analyses were con-
ducted as appropriate.
Complete Analysis
The complete data set is the union of all of the phenotypic sub-
groups and contains 194 kindreds diverse in histopathology, fam-
ily history, and age at onset. This analysis has the greatest power to
detect CRC and colon neoplasia susceptibility genes present in all
phenotypes.
Severe Histopathology
This subgroup was deﬁned for capturing the variability present
within the pathology of adenomatous polyps. Individuals with
polyps that are large in size or that display high-grade dysplasia
are more likely to develop cancer.19,20 We identiﬁed 53 kindreds
with severe histopathology that was deﬁned as CRC, high-grade
dysplasia (HGD), or adenomatous polyps (R1 cm in size) and
that was diagnosed before the age of 65 for all phenotypes (CRC,
HGD, and adenomatous polyps). Because we have published re-
sults for this subgroup,9 only summary information is presented
here for full disclosure of the tests that were performed on the
data and for ease of reference.
Oligopolyposis
This subgroup deﬁned 32 families with multiple colorectal adeno-
mas (Table 1). Families were identiﬁed because at least one individ-
ual in the family had greater than or equal to four adenomatous
polyps. It is well recognized that families with multiple polyps
are representative of a separate and distinct phenotypic subgroup
of colorectal neoplasia, which has a familial inheritance pat-
tern,5,21 although there is no consensus agreement upon the phe-
notypic deﬁnition of these families, and they have been rather
arbitrarily deﬁned in the literature as patients with between 5
and 100 adenomas.21
Young
One of the hallmarks of inherited predisposition to cancer is an
early age at onset. Our young phenotype deﬁned 74 kindreds
with a family mean age at diagnosis %51 years of age (Table 1).
We chose 51 as a cutoff point because (1) themean age at diagnosis
in our sample was 51.4 years; (2) the impact of having a family his-
tory of colon cancer is greater among those diagnosed before the
age of 50;22 and (3) the population prevalence of adenomatous
polyps in individuals between the ages of 40 and 49 is 1.2%.23 Indi-
viduals affected at age%51are in the tail of thepopulationdistribu-
tion and are more likely to have ‘‘hereditary colon neoplasia.’’008
Table 1. Definition of Phenotypic Subgroups Used for the Colon Neoplasia Sibling Study
Subgroup
Number of
Kindreds Agea Selection Criteria
Tumor/Polyp
Size
Definition of Individuals Classified as
Affected Unaffected Unknown
Complete set 194 %65 Two siblings with
neoplasia at age%65
All Definition 1:
Individuals with
histologically verified
colon neoplasiab at
age%65
Definition 2:
Individuals with
negative colonoscopy
or flexible
sigmoidoscopy
Definition 3:
Individuals without
colon screening or
a history of colon
cancer, and/or
adenomatous polyps
at age >65
Severe histopathology 53 %65 Two siblings with
cancer, advanced
adenomas
R1 cm Individuals with colon
cancer or advanced
adenomas (R1 cm)
at age%65
Definition 2 Definition 3 and small
adenomas <1 cm in
size
Oligopolyposis
(multiple polyps)
32 %65 Two siblings withR4
polyps
All Definition 1 Definition 2 Definition 3
Young 74 %51 Two siblings with
neoplasia at age%51
All Definition 1 Definition 2 Definition 3
Colon/breast 33 %65 First degree relative
with breast cancer and
two affected siblings
with colon neoplasia
All Definition 1 or
a history of breast
cancer
Definition 2 and no
history of breast
cancer
Definition 3 and no
history of breast
cancer
Multiple cancer 62 %65 One individual in the
sibship with more
than one primary
cancer site
All Definition 1 or
a history of cancer of
any primary site,
including melanomas
but excluding other
skin cancers
Definition 2 and no
history of other
cancers
Definition 3 and no
history of cancer at
any other primary site
a Age is recorded as the age at diagnosis with cancer, colon adenomatous polyps, or colorectal cancer.
b Colon neoplasia is defined as all individuals with adenomatous polyps of any size and/or colorectal cancer. Note that we do not consider individuals with
hyperplastic polyps to be affected for any of our analyses, and our polyp/histology does not differentiate between adenomas and serrated adenomas.Colon/Breast
This phenotypic subgroup examines the strong clustering of
breast and colon cancer noted in population-based studies.24,25
Cancer geneticists have speculated that there are likely to be
‘‘breast-colon’’ susceptibility genes.26 Families segregating Breast
Cancer 1 (BRCA1 [MIM 113705]), Breast Cancer 2 (BRCA2 [MIM
600185]), and Checkpoint Kinase 2 (CHEK2 [MIM 604373]) muta-
tions have an increased risk for colon cancer.27–32 However, these
relatively rare genes cannot explain the strong clustering of breast
and colon cancer.24 We identiﬁed 33 families with a case of breast
cancer in a FDR and 172 families in which there was an individual
affected with breast cancer in either a FDR or second-degree rela-
tive. Our analysis included only families with a FDR affected
with breast cancer because this allowed us to compare the allele
sharing between breast and colon neoplasia cases (Table 1). Fami-
lies in this subgroup had at least two sibs who were affected with
adenomatous polyps or colon cancer and a sib or mother with
breast cancer.
Multiple Cancer
We identiﬁed 62 families in which at least one individual in the
nuclear family had been diagnosed with cancer at two or more
primary sites (Table 1). Individuals affected with both colon cancer
and colon polyps, but who had no other primary-site cancers,
were not considered to be affected with multiple primary-site
cancers. Melanomaswere considered to be a primary site, but com-
mon skin cancers such as basal and squamous cell carcinomas
were excluded. The rationale behind this subset was to identify
families with a general propensity for developing cancer because
one of the clinical hallmarks of hereditary cancer is an excess ofThemultiple primary malignancies.33 An analysis25 of the Swedish
family-cancer database determined that family history is a major
risk factor for occurrence of multiple primary cancers of the colon
(standardized incidence ratio [SIR] ¼ 59.1), breast (SIR ¼ 7.9), and
skin (SIR ¼ 7.9).
Statistical Methods
We used genotypes from all available siblings and parents to
estimate the proportion of alleles shared IBD for each sib pair,
denoted by the symbol bp, at 2 cM intervals in amultipoint analysis
by using GENIBD in the program package S.A.G.E.9,15 Markers
were polymorphic dinucleotide repeat markers generated by the
Center for Inherited Disease Research (CIDR); genotyping details9
are published and are also available from the authors. The mean
tests are the foundation of the traditional affected-only analyses,
which uses the allele sharing between concordantly affected sib
pairs, to determine the evidence for linkage. In our analyses, con-
ducted with mean tests and the original Haseman-Elston (H-E) re-
gression method, we used the information available from all sib
pairs, with each sib being scored x ¼ 1 if affected or x ¼ 0 if unaf-
fected, as implemented in the S.A.G.E. program SIBPAL. Although
it has been shown that weighted H-E is more powerful
asymptotically,34 weights estimated from the data may demon-
strate numerical instability with smaller size samples. Because
some of our subgroups have a small number of concordantly af-
fected sib pairs (<20), we used the original H-E regression equation
that regresses the squared sib-pair-trait difference y (0, for concor-
dant pairs; 1, for discordant pairs) on bp, in the form of y ¼ aþbbp.
The degree to which allele sharing is associated with concordance
or discordance in affection status determines the signiﬁcance ofAmerican Journal of Human Genetics 82, 723–736, March 2008 725
Table 2. Chromosomal Regions Suggestive of Linkage by the Haseman-Elston Regression Analysis
Group Chromosome (cM)
Concordantly Affected Sib Pairs Discordantly Affected Sib Pairs Concordantly Unaffected Sib Pairs
H-E
p Value
H-E Corrected
(cP)
Allele
Sharing SE p Value
Allele
Sharing SE p Value
Allele
Sharing SE p Value
Complete
1 (171 cM D1S1679) 0.5291 0.0169 0.0433 0.4798 0.0171 0.1215 0.4949 0.0411 0.5486 0.0304 0.1286
3 (206 cM) 0.5227 0.0140 0.0530 0.4846 0.0128 0.1155 0.4998 0.0328 0.5015 0.0311 0.1316
4 (13 cM at D4S2366)a 0.5416 0.0155 0.0038 0.4905 0.0147 0.2607 0.5324 0.0341 0.1727 0.0080 0.0338
4 (93 cM D4S2361) 0.5399 0.0167 0.0088 0.4832 0.0167 0.1468 0.4785 0.0380 0.7125 0.0187 0.0791
5 (96 cM) 0.5064 0.0166 0.3510 0.4847 0.0165 0.1759 0.5470 0.0365 0.1009 0.0431 0.1823
7 (163 cM D7S3070) 0.5267 0.0174 0.0624 0.4565 0.0171 0.0056 0.5361 0.0408 0.1891 0.0011 0.0047
10 (114 cM) 0.5104 0.0179 0.2808 0.5021 0.0170 0.5497 0.5915 0.0397 0.0122 0.0302 0.1277
12 (58 cM) 0.5228 0.0167 0.0807 0.4713 0.0157 0.0351 0.5520 0.0395 0.0960 0.0077 0.0326
15 (42 cM) 0.5318 0.0154 0.0197 0.4884 0.0153 0.2275 0.5173 0.0336 0.3039 0.0205 0.0867
16 (39 cM) 0.5268 0.0159 0.0469 0.4707 0.0150 0.0262 0.4867 0.0358 0.6436 0.0098 0.0415
16 (111 cM D16S3091) 0.5443 0.0162 0.0033 0.4778 0.0158 0.0911 0.4696 0.0363 0.7960 0.0075 0.0317
17 (78 cM) 0.5222 0.0152 0.0726 0.4769 0.0154 0.0681 0.4701 0.0340 0.8079 0.0489 0.2068
19 (40 cM) 0.5123 0.0159 0.2197 0.4809 0.0150 0.1044 0.6021 0.0356 0.0028 0.0155 0.0656
Oligo
1 (259 cM) 0.5189 0.0328 0.2828 0.4247 0.0279 0.0044 0.6198 0.0763 0.0687 0.0078 0.0330
2 (155 cM D2S1399) 0.5313 0.0370 0.1997 0.4574 0.0426 0.1609 0.6937 0.0892 0.0231 0.0160 0.0677
3 (90 cM D3S4542) 0.5695 0.0374 0.0336 0.4386 0.0375 0.0533 0.4752 0.0687 0.6380 0.0163 0.0689
3 (216 cM D3S2418) 0.5714 0.0346 0.0213 0.4111 0.0331 0.0045 0.4255 0.0601 0.8825 0.0040 0.0169
4 (158 cM D4S1629) 0.5188 0.0328 0.2836 0.4357 0.0388 0.0513 0.6392 0.0754 0.0423 0.0218 0.0922
10 (59 cM D10S1426) 0.4852 0.0336 0.6688 0.4211 0.0374 0.0193 0.5536 0.0907 0.2818 0.0475 0.2009
12 (62 cM) 0.5689 0.0348 0.0473 0.4674 0.0327 0.1616 0.5546 0.0693 0.2214 0.0301 0.1273
12 (81 cM D12S375) 0.5400 0.0414 0.1685 0.4514 0.0425 0.1287 0.5877 0.0680 0.1085 0.0345 0.1459
14 (116 cM) 0.5412 0.0359 0.1280 0.4094 0.0313 0.0025 0.5463 0.0601 0.2266 0.0018 0.0076
15 (28 cM) 0.5244 0.0299 0.2091 0.4610 0.0287 0.0901 0.6414 0.0640 0.0216 0.0077 0.0326
16 (93 cM) 0.5827 0.0295 0.0028 0.4415 0.0325 0.0382 0.4967 0.0785 0.5163 0.0026 0.0110
Young
4 (99 cM) 0.5499 0.0230 0.0159 0.4863 0.0207 0.2560 0.5486 0.0512 0.1756 0.0163 0.0689
5 (96 cM) 0.5188 0.0252 0.2289 0.4638 0.0233 0.0607 0.6232 0.0673 0.0396 0.0183 0.0774
5 (178 cM) 0.5102 0.0249 0.3411 0.4568 0.0208 0.0194 0.5758 0.0526 0.0809 0.0211 0.0893
7 (162 cM at D7S3070)0.5116 0.0253 0.3233 0.4500 0.0248 0.0228 0.5938 0.0660 0.0840 0.0167 0.0706
8 (139 cM) 0.5292 0.0271 0.1409 0.4817 0.0235 0.2195 0.6077 0.0644 0.0535 0.0444 0.1878
11 (22 cM) 0.5142 0.0253 0.2875 0.4628 0.0225 0.0508 0.6379 0.0715 0.0326 0.0190 0.0804
12 (56 cM c12S1916) 0.5152 0.2638 0.2817 0.4553 0.0250 0.0380 0.5588 0.0690 0.2007 0.0302 0.1277
12 (72 cM) 0.5045 0.0231 0.4216 0.4674 0.0210 0.0620 0.5940 0.0529 0.0439 0.0488 0.2064
12 (88 cM) 0.5238 0.0240 0.1617 0.4683 0.0208 0.0650 0.6148 0.0646 0.0438 0.0135 0.0571
15 (20 cM at D15S165) 0.5412 0.0168 0.0077 0.4722 0.0161 0.0439 0.5498 0.0409 0.1173 0.0009 0.0038
16 (35 cM) 0.5117 0.0232 0.3068 0.4634 0.0221 0.0498 0.5482 0.5074 0.2045 0.0418 0.1768
19 (38 cM) 0.5150 0.0241 0.2667 0.4704 0.0217 0.0876 0.6292 0.0517 0.0097 0.0254 0.1074
20 (2 cM at D20S103) 0.5137 0.0244 0.2874 0.4618 0.0211 0.0366 0.5469 0.0711 0.2574 0.0364 0.1540
21 (13 cM at D21S1437)0.5542 0.0248 0.0152 0.4781 0.0237 0.1792 0.4726 0.0657 0.6596 0.0264 0.1117
Colon/Breast
1 (141 cM) 0.5405 0.0390 0.1516 0.4181 0.0366 0.0142 0.5718 0.0927 0.2244 0.0067 0.0283
2 (222 cM) 0.6011 0.0327 0.0014 0.4874 0.0271 0.3219 0.4793 0.0508 0.6554 0.0150 0.0635
8 (78 cM) 0.5547 0.0397 0.0868 0.4543 0.0343 0.0937 0.5005 0.0710 0.4968 0.0354 0.1497
10 (168 cM) 0.5590 0.0325 0.0372 0.4560 0.0360 0.0775 0.4254 0.0591 0.8865 0.0366 0.1548
13 (26 cM at D13S1493)0.5742 0.0398 0.0337 0.4307 0.0383 0.0388 0.5194 0.0727 0.3960 0.0070 0.0296
17 (1 cM at D17s1308) 0.5501 0.0340 0.0732 0.4567 0.0291 0.0710 0.5597 0.0671 0.1928 0.0086 0.0364
18 (53 cM at D18s877) 0.5279 0.0369 0.2259 0.4473 0.0360 0.0738 0.5825 0.0618 0.0991 0.0252 0.1066
21 (12 cM at D21s1437) 0.5860 0.0362 0.0102 0.4268 0.0274 0.0046 0.5258 0.0704 0.3589 0.0003 0.0013
21 (59 cM at D21S446) 0.5126 0.0328 0.3507 0.4232 0.0316 0.0087 0.5835 0.0500 0.0562 0.0086 0.0364
Multiple
1 (102 cM at D1S1665)0.5718 0.0250 0.0024 0.4082 0.0282 0.0007 0.4344 0.0688 0.8222 0.000070.00029
1 (175 cM) 0.5476 0.0258 0.0033 0.4422 0.0303 0.0295 0.4100 0.0921 0.8281 0.0170 0.0719
5 (82 cM at D5S424) 0.5322 0.0243 0.0938 0.4488 0.0281 0.0353 0.5812 0.0637 0.1103 0.0068 0.0288
7 (163 cM at D7S3070)0.5050 0.0270 0.4208 0.4366 0.0300 0.0185 0.5393 0.0994 0.3487 0.0342 0.1447
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Table 2. Continued
Group Chromosome (cM)
Concordantly Affected Sib Pairs Discordantly Affected Sib Pairs Concordantly Unaffected Sib Pairs
H-E
p Value
H-E Corrected
(cP)
Allele
Sharing SE p Value
Allele
Sharing SE p Value
Allele
Sharing SE p Value
9 (84 cM) 0.5336 0.0245 0.0859 0.4484 0.0275 0.0320 0.4466 0.0738 0.7587 0.0064 0.0271
9 (110 cM) 0.5224 0.0273 0.2070 0.4484 0.0258 0.0241 0.4322 0.0976 0.7511 0.0191 0.0808
16 (105 cM) 0.5227 0.0232 0.1649 0.4440 0.0246 0.0125 0.4526 0.0797 0.7197 0.0182 0.0770
a Entries in gray-shaded rows indicate where the H-E regression coefficient remained statistically significant after correction formultiple hypothesis testing.the regression coefﬁcient b. Reported p values were conﬁrmed by
comparison to a Monte Carlo sample of the permutation distribu-
tion created by permutation of the allele-sharing values relative
to the pair labels (concordant or discordant). Permutations were
done both within sibships and across sibships of the same size,
sufﬁcient in number for assuring with 95% conﬁdence that the
estimated p value was within 5% of the true p value. The number
of permutations ranged from 0 to 1million (chromosome 1, multi-
ple-cancer subgroup). We used matrix spectral decomposition
(matSpD), a variant of SNPSpD,35 to estimate the number of inde-
pendent phenotypes being analyzed (n ¼ 4.23). This was applied
as a Sidak correction,36,37 which is less conservative than the Bon-
ferroni correction, to the p value obtained from the permutation
distribution. Throughout this work, this corrected p value is de-
noted as cP; otherwise all reported p values were uncorrected for
multiple testing. All p values were estimated from the permutation
distribution.
Association testing was performed on peak marker locations
with ASSOC in the S.A.G.E. programming package. We tested all
alleles at the microsatellites closest to the peak locations listed in
Table 2 for associationwith the corresponding phenotype by using
ASSOC, which can test for association by using a likelihood ratio
test under a logistic model allowing for the presence of familial
correlations. We found no evidence for association (minimum
p ¼ 0.07).
Results
Here, we present the detailed results of the analyses of the
complete set of 194 kindreds and of four phenotypic sub-
groups (oligopolyposis, young, colon/breast, and multiple
cancer), along with summary results from our primary se-
vere histopathology phenotype published previously.9 Of
particular interest were regions for which both the H-E
regression and the mean tests indicated ‘‘signiﬁcant’’ link-
age, deﬁned as regions with a p value% 0.016. This corre-
sponded to a LOD > 1.0, reﬂecting a level of signiﬁcance
appropriate to control type II error. We report the most sig-
niﬁcant H-E regression p value for the region, along with
the allele-sharing estimates, so that the reader can weigh
the evidence resulting from both measures. Results from
the H-E regression analyses have been plotted for all chro-
mosomes and phenotypes (Figures 1 and 2).
Complete Analysis
After permutation testing and correction for multiple hy-
pothesis testing, signiﬁcant evidence for linkage for theThe Aentire set of 194 kindreds was demonstrated for ﬁve regions
on chromosomes 4, 7, 12, and 16 (Tables 2 and 3). Themost
signiﬁcant signal was located at marker D7S3070 (163 cM;
p ¼ 0.0011) on chromosome 7, ﬂanked by markers
D7S2195 (155 cM) and D7S3058 (175 cM). This peak was
also observed in the severe histopathology subgroup (Fig-
ure 1); it has not been previously identiﬁed with CRC or co-
lonpolyps.AtD4S2366 (13 cM;p¼0.0080), theﬁrstmarker
on the chromosome demonstrated excess allele sharing
among concordantly affected sib pairs (bp ¼ 05416; p ¼
0.0038). For chromosome 16, the peak at marker
D16S3094 (111 cM) was ﬂanked by markers D16S3096
(99 cM) and D16S539 (125 cM) and was observed in the
oligopolyposis, severe-histopathology, andmultiple-cancer
subgroups.
Several of our signiﬁcant linkage peaks (uncorrected)
overlapped with previously identiﬁed candidate genes, in-
cluding the hereditary mixed polyposis syndrome (HMPS/
CRAC1 [MIM 601228]) locus on chromosome 15q15.3-
q22.1 (H-E regression, p ¼ 0.02; Table 2), and the region
at 128 cM on chromosome 10 (Table 3), which overlapped
both the BMPR1A locus, associated with HMPS38 and
ANXA11, a putative low-penetrance gene for colorectal
cancer.39
Severe Histopathology
The severe-histopathology phenotype was our primary
analysis phenotypebecausewepreviously identiﬁed a chro-
mosomal region on 9q22.2-31.2 as a putative susceptibility
locus for colorectal neoplasia9 (CRCS1 [MIM 608812]).
Linkage to this region has recently been conﬁrmed in stud-
ies fromSweden and theUK.10,11 Results for this phenotype
for the H-E regression are provided on the genome scan
plots for ease of reference to our current ﬁndings and full-
reporting purposes (Figure 1). We note that this is the orig-
inal subgroup analyzed in our previous publication in
which the full results for the mean tests and H-E regression
can be found.9
Oligopolyposis or Multiple Polyps
After permutation testing and correction for multiple test-
ing, there were ﬁve regions (chromosomes 1, 3, 14, 15,
and 16) for which therewas signiﬁcant evidence for linkage
(Tables2 and3). Forchromosome15 (Table2), the identiﬁed
linkage signal peaked at 28 cM (p¼ 0.008) betweenmarkers
D15S165 (20 cM) and marker D15S1012 (36 cM). Thesemerican Journal of Human Genetics 82, 723–736, March 2008 727
Figure 1. Plots for Chromosomes 1–12 for All Subgroups
Distance is plotted along the x axis and bothlog10 (p value) denoted as pP and the LOD are plotted on the y axis for reference purposes.
Reference lines at a LOD of 2 and 3 are provided, and significant data points are labeled with the phenotype location and pP value.markers overlap the HMPS/CRAC1 region associated with
HMPS in families of Ashkenazi descent identiﬁed by
Tomlinson and Jaeger,17,18 who reported a peak at marker
D15S1007 (29.9 cM), ﬂanked by markers D15S1031
(26 cM) andD15S118 (31.0 cM). The concordance between
the two studies is illustrated in Figures 2 and 3. This region
on chromosome 15q14 was identiﬁed in the complete set
(p ¼ 0.018), oligopolyposis (p ¼ 0.003), and young (p ¼
0.0009) subgroups. We noted that the signiﬁcance levels
met and exceeded the thresholds required for signiﬁcant
replication of ﬁndings.40,41 Jaegar et al.17 reported a com-
mon haplotype that is shared in a large family of Ashkenazi
descent and that is characterized by anuncommonand spe-
ciﬁc phenotype of multiple colorectal polyps (deﬁned as
greater than three polyps). To determine the effect of the
families of Ashkenazi Jewish origin, we reanalyzed our link-728 The American Journal of Human Genetics 82, 723–736, Marchage results after excluding the data from these families and
found a subsequent increase in the linkage signal (i.e., de-
crease in the p value) was observed in all subgroups (Table
4 and Figure 3), indicating that in our sample, families of
non-Jewish European ancestry were linked to this region.
The p value was validated by 33,412 replicates in a Monte
Carlo sample of the permutation distribution. To further
reﬁne the phenotype of families linking to this region, we
identiﬁedand rankordered the families linked to this region
and examined the phenotype distributions in the top 12
families (see Table 5). We found three of the four highest
ranked families met breast/colon criteria and two of these
met young, breast/colon, and multiple polyp criteria.
Additional regions of interest were located at ~259 cM
on chromosome 1 (H-E, p ¼ 0.0078) and was ﬂanked by
markers D1S549 (240 cM) and D1S1609 (275 cM) (Table2008
Figure 2. Plots for Chromosomes 13–22 for All Subgroups
Distance is plotted along the x axis and bothlog10 (p value) denoted as pP and the LOD are plotted on the y axis for reference purposes.
Reference lines at a LOD of 2 and 3 are provided, and significant data points are labeled with the phenotype location and pP value.2). This region includes EXO1, which maps to between
260 and 268 cM, depending on the reference genetic map
(Marshﬁeld or deCODE) used. EXO1, involved in DNA re-
pair, is speculated to be involved in the development of
CRC,39,42,43 and there is evidence to suggest that a recessive
mode of inheritance for this locus.39 Because concordant
sib pairs shared a greater proportion of two alleles IBD
(0.39 for concordantly unaffected; 0.28 for concordantly af-
fected) than the expected proportion (0.25), and because
the proportion for discordant pairs was only 0.13 (p ¼
0.0001), these observations were consistent with linkage.44
For chromosome 3, the signal at marker D3S2418 (216
cM), ﬂanked by markers D3S2427 (188 cM) and D3S1311
(226 cM), included the CRC candidate geneMFI2antigen,39
which is located at 224 cM. For chromosome 14, the signal
at 116 cM (H-E, p ¼ 0.0018) was ﬂanked by markers
c14S1937 (96 cM) and D14S1436 (126 cM). This region in-
cluded the CRC candidate gene GOLGA5 (108 cM).39 For
chromosome 16, the signal extended across a large region
from D16S540 (58 cM) to D16S539 (125 cM) and peaked
at ~93 cM (H-E, p ¼ 0.0026). Furthermore, there is no evi-
dence for linkage to MutY-homolog (MYH [MIM 604933]),Thewhich is associated with a multiple colorectal adenoma
phenotype, although the frequency is highest in patients
with greater than ten polyps.45,46
Young
The most signiﬁcant observation for both H-E regression
and the mean tests and the only signal that survives
multiple correction (young phenotype) was marker
D15S165 (20 cM; p ¼ 0.0009), located on chromosome 15
in the region of theHMPS/CRAC1 locus (Table 4).We tested
the sensitivity of the analysis to the inclusion of data from
the Ashkenazi families. When we excluded the data from
these families, we observed a decrease in the p value, indi-
cating that linkage to the region was generated by the
data from families of non-Jewish European descent (i.e., ex-
cluding families of Jewish descent, Table 4). We found that
six of the nine locations that had been identiﬁed because of
excess allele sharing in concordantly affected sib pairs also
showed excess sharing in the discordant sib pairs, high-
lighting the importance of evaluating data from discor-
dant sib pairs (Table 3). For chromosomes 2, 4, and 7, all sib
pairs have estimated allele sharing that exceeds 0.50,American Journal of Human Genetics 82, 723–736, March 2008 729
Table 3. Chromosomal Regions Suggestive of Linkage by the Mean Tests
Group Chromosome (cM)
Concordantly Affected Sib
Pairs
Discordantly Affected Sib
Pairs
Concordantly Unaffected Sib
Pairs
H-Ea
p Value
Corrected H-E
p Value (cP)
Allele
Sharing SE p Value
Allele
Sharing SE p Value
Allele
Sharing SE p Value
Full
1 (171 cM D1S1679) 0.5291 0.0169 0.0433 0.4798 0.0171 0.1215 0.4949 0.0411 0.5486 0.0304 0.1286
2 (94 cM D2S1394) 0.5332 0.0174 0.0286 0.5240 0.0153 0.9406 0.4830 0.0379 0.6716 0.4653 1.0000
4 (13 cM at D4S2366)b 0.5416 0.0155 0.0038 0.4905 0.0147 0.2607 0.5324 0.0341 0.1727 0.0080 0.0338
4 (99 cM) 0.5391 0.0152 0.0053 0.4940 0.0144 0.3398 0.5094 0.0346 0.3925 0.0219 0.0926
6 (152 cM) 0.5323 0.0149 0.0156 0.5073 0.0139 0.7015 0.4925 0.0351 0.7835 0.2048 0.8663
9 (95 cM D9S283) 0.5306 0.0170 0.0362 0.5059 0.0165 0.6400 0.4731 0.0449 0.7404 0.2536 1.0000
10 (128 cM) 0.5277 0.0157 0.0396 0.5152 0.0156 0.8348 0.5426 0.0354 0.1167 0.2166 0.9162
12 (94 cM) 0.5393 0.0176 0.0133 0.4977 0.0159 0.4435 0.5097 0.0388 0.4016 0.2117 0.8955
15 (43 cM D15S659)c 0.5379 0.0169 0.0127 0.4884 0.0167 0.2450 0.5096 0.0368 0.3967 0.0213 0.0901
16 (44 cM D16S403) 0.5301 0.0172 0.0410 0.4700 0.0166 0.0365 0.4893 0.0405 0.6033 0.0166 0.0702
16 (83 cM) 0.5373 0.0139 0.0038 0.5078 0.0139 0.7134 0.4493 0.0302 0.9508 0.2540 1.0000
18 (13 cM D18S976) 0.5297 0.0162 0.0343 0.5294 0.0159 0.9672 0.4516 0.0339 0.9203 0.7583 1.0000
Oligo
3 (84 cM) 0.5657 0.0351 0.0329 0.4482 0.0364 0.0823 0.4680 0.0674 0.6786 0.0326 0.1379
3 (207 cM D3S2398) 0.5812 0.0352 0.0120 0.4290 0.0381 0.0337 0.3690 0.0674 0.9644 0.0147 0.0622
4 (13 cM) 0.5751 0.0310 0.0090 0.5185 0.0358 0.6970 0.5595 0.0701 0.2046 0.1400 0.5922
5 (54 cM) 0.5697 0.0320 0.0164 0.5220 0.0361 0.7273 0.3937 0.0587 0.9549 0.4336 1.0000
7 (108 cM D7S821) 0.5782 0.0358 0.0161 0.5561 0.0396 0.9197 0.3516 0.0728 0.9700 0.7072 1.0000
10 (4 cM D10S1435) 0.5723 0.0336 0.0173 0.5447 0.0330 0.9100 0.5242 0.0849 0.3894 0.3277 1.0000
11 (9 cM D11S2362) 0.5744 0.0347 0.0181 0.5218 0.0377 0.7177 0.4623 0.0990 0.6456 0.3765 1.0000
12 (64 cM) 0.5586 0.0352 0.0502 0.4644 0.0328 0.1571 0.5538 0.0685 0.2224 0.0308 0.1303
15 (43 cM D15S659) 0.5707 0.0345 0.0219 0.4604 0.0402 0.1643 0.5831 0.0936 0.1941 0.0277 0.1172
16 (64 cM D16S3396) 0.5712 0.0366 0.0278 0.4347 0.0351 0.0339 0.4433 0.0753 0.7682 0.0185 0.0783
16 (89 cM) 0.5962 0.0299 0.0009 0.4510 0.0371 0.0961 0.4909 0.0807 0.5437 0.0043 0.0182
17 (45 cM D17S2196) 0.5982 0.0355 0.0036 0.4847 0.0414 0.3568 0.4201 0.0582 0.9046 0.0722 0.3054
Young
2 (40 cM) 0.5416 0.0236 0.0261 0.5146 0.0232 0.7350 0.5230 0.0681 0.3692 0.1907 0.8067
4 (113 cM) 0.5604 0.0231 0.0050 0.5177 0.0229 0.7800 0.5733 0.0658 0.1378 0.0807 0.3414
7 (71 cM D7S1818) 0.5397 0.0237 0.0480 0.5139 0.0244 0.7153 0.6195 0.0684 0.0465 0.1330 0.5626
10 (130 cM) 0.5509 0.0245 0.0196 0.5137 0.0234 0.7212 0.4509 0.5490 0.8100 0.2392 1.0000
15 (20 cM) 0.5405 0.0162 0.0067 0.4745 0.0158 0.0555 0.5547 0.0394 0.0884 0.0009 0.0038
16 (93 cM) 0.5406 0.0220 0.0338 0.5092 0.0217 0.6642 0.3946 0.0611 0.9513 0.6311 1.0000
16 (110 cM D16S3091) 0.5506 0.0241 0.0185 0.4980 0.0228 0.4652 0.3738 0.0602 0.9767 0.1955 0.8270
18 (12 cM at D18S976) 0.5418 0.0237 0.0219 0.5224 0.0238 0.8267 0.4918 0.0544 0.5586 0.2883 1.0000
21 (13 cM at D21S1437) 0.5542 0.0248 0.0152 0.4781 0.0237 0.1792 0.4726 0.0657 0.6596 0.0264 0.1117
Colon/Breast
1 (177 cM) 0.5901 0.0372 0.0092 0.5071 0.0365 0.5768 0.4215 0.0762 0.8303 0.1882 0.7961
2 (224 cM) 0.6000 0.0318 0.0012 0.4875 0.0252 0.3119 0.4680 0.0515 0.7285 0.0152 0.0643
3 (6 cM at D3S2287) 0.5883 0.0403 0.0161 0.5425 0.0372 0.8709 0.4912 0.0726 0.5472 0.3272 1.0000
7 (86 cM at D7S2204) 0.6007 0.0435 0.0119 0.4969 0.0388 0.4686 0.3553 0.0736 0.9674 0.1968 0.8325
7 (119 cM) 0.5933 0.0315 0.0021 0.5220 0.0353 0.7323 0.4495 0.0744 0.7468 0.2306 0.9754
10 (82 cM) 0.5885 0.0393 0.0138 0.5205 0.3993 0.6957 0.4735 0.0755 0.6346 0.2269 0.9598
10 (170 cM) 0.5618 0.0336 0.0355 0.4520 0.0328 0.0744 0.4129 0.0656 0.8976 0.0384 0.1624
11 (58 cM at D11S1344) 0.5716 0.0390 0.0356 0.5108 0.0327 0.6298 0.3571 0.0619 0.9833 0.4218 1.0000
13 (26 cM at D13S1493) 0.5742 0.0398 0.0337 0.4307 0.0383 0.0388 0.5194 0.0727 0.3960 0.0070 0.0296
17 (82 cM at D17S1290) 0.5865 0.0400 0.0175 0.4676 0.0383 0.2009 0.4346 0.0756 0.8000 0.3271 1.0000
19 (16 cM) 0.5572 0.0313 0.0360 0.5312 0.0340 0.8190 0.6035 0.0548 0.0392 0.1940 0.8206
19 (72 cM) 0.5666 0.0349 0.0304 0.5465 0.0348 0.9069 0.4108 0.0777 0.8657 0.5986 1.0000
21 (12 cM at D21S1437) 0.5860 0.0362 0.0102 0.4268 0.0274 0.0046 0.5258 0.0704 0.3589 0.0003 0.0013
Multiple
1 (102 cM at D1S1665) 0.5718 0.0250 0.0024 0.4082 0.0282 0.0007 0.4344 0.0688 0.8222 0.00007 0.0003
1 (176 cM at D1S1677) 0.5507 0.0258 0.0257 0.4433 0.0303 0.0324 0.4010 0.0942 0.8452 0.0234 0.0990
2 (38 cM at D2S1360) 0.5749 0.0276 0.0037 0.4900 0.0330 0.3844 0.4461 0.1105 0.6837 0.0518 0.2191
2 (258 cM) 0.5520 0.0237 0.0151 0.5251 0.0274 0.8187 0.6361 0.0816 0.0574 0.1591 0.6730
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Table 3. Continued
Group Chromosome (cM)
Concordantly Affected Sib
Pairs
Discordantly Affected Sib
Pairs
Concordantly Unaffected Sib
Pairs
H-Ea
p Value
Corrected H-E
p Value (cP)
Allele
Sharing SE p Value
Allele
Sharing SE p Value
Allele
Sharing SE p Value
4 (109 cM) 0.5434 0.0257 0.0467 0.4862 0.0261 0.3008 0.5359 0.0882 0.3447 0.1318 0.5575
5 (40 cM at D5S2848) 0.5521 0.0282 0.0335 0.5356 0.0324 0.8633 0.4901 0.1108 0.5350 0.4103 1.0000
7 (108 cM) 0.5636 0.0259 0.0077 0.5152 0.0288 0.7005 0.4501 0.0709 0.7540 0.1691 0.7153
8 (82 cM) 0.5488 0.0285 0.0449 0.5039 0.0289 0.5530 0.4784 0.0865 0.5968 0.1904 0.8054
10 (135 cM at D10S1237) 0.5484 0.0270 0.0380 0.5064 0.0279 0.5914 0.5627 0.0589 0.1495 0.1174 0.4966
12 (12 cM) 0.5421 0.0240 0.0412 0.5361 0.0274 0.9049 0.5453 0.0741 0.2798 0.4321 1.0000
12 (92 cM) 0.5564 0.0272 0.0205 0.5238 0.0258 0.8211 0.4660 0.0916 0.6420 0.2885 1.0000
a H-E: Haseman-Elston regression method.
b Entries in gray-shaded rows indicate regions in which there was an allele-sharing pattern consistent with linkage and the H-E regression coefficient was
significant after correction for multiple hypothesis testing.
c Italicized entries indicate demonstrated linkage to the HMPS/CRAC1 locus.an observation that is not consistent with linkage (Table
3). This further highlights the need to weigh the evidence
for linkage with the totality of evidence rather than place
reliance upon excess sharing in affected sib pairs alone.
Colon/Breast
In the 33 colon/breast kindreds, there were several signals
of considerable interest on chromosomes 1, 13, 17, and 21
(Table 2). For chromosome 1, the signal at 141 cM was
ﬂanked by markers D1S1588 (126 cM) and D1S534 (152
cM), in a region frequently altered in a number of solid
tumors, including breast cancer47 and colon cancer;48 link-
age to this region was also observed with the multiple-can-
cer phenotype. The signal at marker D13S1493, identiﬁed
by both H-E regression and the mean tests, was within
5 cM of BRCA2; we did not see a signal in the region of
BRCA1 (17q21) or CHEK2 (22q11-12). We observed linkage
to marker D17S1308 (17p), in close proximity to the can-
didate gene Hypermethylated in Cancer 1 (HIC1 [MIM
603825]). There was evidence for linkage to much of chro-mosome 21, with two linkage peaks, one at D21S1437 (~12
cM), ﬂanked by markers D21S1432 (4 cM) and D21S1440
(37 cM), and the second peak at the last marker on the
chromosome, D21S446 (59 cM).
One successful strategy to combat locus heterogeneity is
to exclude families demonstrating linkage to known loci.
To further evaluate our evidence for linkage to chromo-
somes 17 and 21, we identiﬁed 11 families linked to
BRCA2 (Table 6), excluded these families from the analysis,
and reevaluated the evidence for linkage to chromosomes
13, 17, and 21. As expected, linkage to D13S1493 (BRCA2)
disappears (Table 7), as does the evidence for linkage at
D21S1437. The signals for chromosomes 17 and for 21 at
57 cM remained. All evidence for linkage to D21S1437
was being provided by the same 11 families that demon-
strate evidence for linkage to BRCA2. When we included
markers D13S1493 (BRCA2) andD21S1437 in amultiple re-
gression equation and tested for interaction (i.e., departure
from additive effects), both markers remained statistically
signiﬁcant (for D13S1493, p ¼ 0.015; and for D21S1437,
Figure 3. Overlap with HMPS/CRAC1
Locus
Distance is plotted along the x axis and
both log10 (p value) denoted as pP and
the LOD are plotted on the y axis for refer-
ence purposes. Reference lines at a LOD of
2 and 3 are provided, and significant data
points are labeled with the phenotype
location and pP value. NJ indicates that
families of Jewish ancestry have been
removed from the analysis.
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Table 4. Haseman-Elston and Mean Tests Results for Chromosome 15 in the Complete Sample, Oligopolyposis, and Young
Subgroups
Sample Distance (cM)
Concordantly Affected Sib Pairs Discordantly Affected Sib Pairs Concordantly Unaffected Sib Pairs
H-E p ValueAllele Sharing SE p Value Allele Sharing SE p Value Allele Sharing SE p Value
Completea (24 cM) 0.5231 0.0113 0.0214 0.4911 0.0112 0.2152 0.5137 0.0263 0.3013 0.0225
Complete—AJb (28 cM) 0.5312 0.0146 0.0166 0.4891 0.0138 0.2414 0.5133 0.0291 0.3248 0.0180
Oligoc (28 cM) 0.5299 0.0279 0.1587 0.4614 0.0292 0.0990 0.6407 0.0661 0.0250 0.0091
Oligo—AJd (28 cM) 0.5318 0.0357 0.1879 0.4558 0.0300 0.0928 0.6739 0.0741 0.0170 0.0037
Younge (20 cM at D15S165) 0.5412 0.0168 0.0077 0.4722 0.0161 0.0439 0.5498 0.0409 0.1173 0.0009
Young—AJf (20 cM at D15S165) 0.5435 0.0169 0.0055 0.4722 0.0163 0.0454 0.5498 0.0409 0.1173 0.0007
a Complete set of families (n ¼ 194).
b Complete set without 13 families of Ashkenazi Jewish (AJ) descent (n ¼ 181).
c All families in oligopolyposis phenotypic subgroup (n ¼ 32).
d Oligopolyposis subgroup without three AJ families (n ¼ 29).
e All families in the Young subgroup (n ¼ 74).
f Young subgroup without four AJ families (n ¼ 70).p ¼ 0.00019), with no evidence for interaction (epistasis)
between the two markers. This leads to the conclusion
that the two loci are segregating together in these 11 fami-
lies but are either (1) acting in an additive fashion or (2) seg-
regating together by chance alone. We note that two of the
11 families linked to BRCA2 also demonstrate evidence for
linkage to HMPS/CRAC1.
Multiple Cancer
There were three peaks of interest in the multiple-cancer
phenotype, on chromosomes 1, 5, and 9 (Tables 2 and 3).
Statistically, the most signiﬁcant linkage signal across all
phenotypic subgroups was found at marker D1S1665 (102
cM; p ¼ 0.00007) with the multiple-cancer phenotype.
This signal was generated by a strong increase in allele shar-
ing among concordantly affected sib pairs (bp ¼ 0.5718;
p ¼ 0.002) and a corresponding decrease in allele sharing
among discordant sib pairs (bp¼ 0.4082; p¼ 0.0007). These
estimates indicated that being either affected or unaffected
could be predicted by the allele sharing at D1S1665 and are
consistent with a putative susceptibility locus. In the chro-
mosomeplots (Figure 1), there appeared tobe three separate
peaks: one at 102 cM, one at 137 cM, and a third at 175 cM.
The secondpeak at137 cM(Figure1)wasnot reﬂected in the
data in Tables 2 or 3 because both the allele-sharing esti-
mates and the H-E regression values remained statistically
signiﬁcant for the entire region from 95 cM to 157 cM;
thedipobserved in theplotwas relative. These observationswere consistent with linked susceptibility loci. To further
delineate these peaks, we used the weighted versions of
the H-E regression (W2, W3, and W4), and these resulted
in only a single peak, in the region of 137 cM (Figure 4).
Weighted versions are asymptotically more powerful; how-
ever,withonly17concordantlyunaffectedpairs in themul-
tiple-cancer subgroup, the original H-E regression, which
combined all concordant pairs, was probably more stable
and accurate. Allele-sharing estimates for marker D1S1631
(second peak) demonstrate excess allele sharing for the
concordantly unaffected pairs (bp ¼ 0.6767; p ¼ 0.013),
decreased sharing for the discordant pairs (bp ¼ 0.4228;
p ¼ 0.007), and a nonsigniﬁcant increase in the concor-
dantly affected pairs (bp¼ 0.5162; p¼ 0.282). All these ﬁnd-
ings are consistent with a protective allele. Our results for
chromosome 1 are consistent with two linked loci, at
102 cM and at 137 cM, respectively.
Two other signals of interest are located on chromosome
5 at D5S424, ﬂanked by markers D5S2500 at 69 cM and
D5S1725 at 98 cM, and on chromosome 9 at 84 cM,
ﬂanked by markers D9S1122 at 72 cM and D9S283 at
95 cM; both regions show increased allele sharing between
concordantly affected pairs and a decrease in allele sharing
for discordant pairs, a pattern that is consistent with link-
age. Marker D5S424 is linked with bladder and ovarian
cancer.49–51 The peak on chromosome 9 at 84 cM is
20 cM away from the 9q22.2 region linked to colorectal
neoplasia in our previous paper.9Table 5. Distribution of Phenotypes for the 13 Families Demonstrating Linkage to the HMPS/CRAC1 Locus
Families with Both Affected
and Unaffected Pairs (n)
Families with Multiple
Polyps (>4 polyps)
Colon/Breast
Families
Number of Individuals
with CRC
Number of
Adenomatous Polypsa
Average Number of Polyps
per Affected Indivdiual
Full Set 12 of 13 8b 3c 8 80 3.2
a Our polyp histology does not include hyperplastic polyps, and we cannot differentiate serrated adenomas.
b Three of the four top-ranked families demonstrating linkage to HMPS/CRAC1 also meet criteria for breast/colon, and two of the families were classified as
potential attenuated FAP when entering the study.
c We note that two of these families also demonstrate linkage to BRCA2.
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Table 6. Distribution of Phenotypes for the 33 Families in the Colon/Breast Subgroup
Families with
Affected and
Unaffected Pairs
Families with
Multiple Polyps
(>4 polyps) Breast Cancers
Number of
Individuals
with CRC
Number of
Individuals with
Adenomatous Polyps
Distribution
of Ten Double Primaries
Full Set 24 5 (all MSI stable) 16 (mom) 12 (sibling)
1 mother and daughter
2 sister-sister pairs
13 67 3 Breast/Colon 2 Breast
and HGD 5 Breast and
polyps
11 Families Linked
to BRCA2
9 2 7 (mom) 4 (sibling,
1 bilateral breast diagnosed
at age 49 and 53)
5 18 2 Breast/Colon 2 Breast
and polypsDiscussion
Colon neoplasia is undoubtedly a heterogeneous disease,
both in its genetic origins (allelic and locus) and in pheno-
typic presentation. Our strategy to combat genetic hetero-
geneity utilized clinical information, such as the size and
number of polyps, histopathology, family history, age at
onset, and other primary cancers, to identify families
with similar clinical features, on the presumption that
this would result inmore genetic homogeneity and, hence,
would increase the power to detect linkage signals.
Our results demonstrated that phenotypic classiﬁcation
could be used to identify linkage peaks associatedwith phe-
notypic subgroups. These linkage peaks had been masked
in the analysis of the complete set of data, and many of
the most interesting linkage signals overlapped with previ-
ously identiﬁed susceptibility genes (BRCA2 and HMPS/
CRAC1) and candidate regions, suggesting that they are
true linkage signals. Analyzing different phenotypic sub-
groups provides an opportunity to compare the evidence
for linkage among phenotypic subgroups. We identiﬁed
linkage at the level of genome-wide signiﬁcance for a
replication study to the HMPS/CRAC1 locus in the full
(p ¼ 0.018), oligopolyposis (p ¼ 0.003), and young (p ¼
0.0007) subgroups. The HMPS/CRAC1 locus has previously
only been reported with the uncommon and speciﬁc phe-
notype of HPMS, in families of Ashkenazi descent.17 Our
analysis provides compelling new evidence linking this lo-
cus to families of European descent with a young age at on-
set (%51) and/or multiple polyps, thereby conﬁrming and
generalizing the ﬁndings of Jaegar et al.,17 in a unique pop-
ulation of colon neoplasia families, by utilizing a study de-
sign with built-in ‘‘matched’’-sibling controls and making
the study robust to type I error.6,9 Furthermore, after correc-tion for multiple phenotype testing and with permutation
testing, these results remained statistically signiﬁcant.
Linkage to this locus is not identiﬁed in kindreds with the
severe histopathology phenotype (see Figures 1 and 2), in-
dicating that the HMPS/CRAC1 locus may be involved in
the development of colorectal polyps but not necessarily
involved with progression to CRC.
In the colon/breast subgroup, we identiﬁed 11 families
that evidenced linkage to BRCA2 and to chromosome 21
at D21S1437. BRCA2 and D21S1437 are segregating to-
gether but acting independently. Further study of families
segregating BRCA2mutations, with and without colorectal
cancer, will be useful in determining the importance of the
linkage signal at D21S1437. After we had excluded data
from families linked to BRCA2, the most statistically signif-
icant linkage peaks were at marker D17S1308 on chro-
mosome 17 and at 57 cM on chromosome 21 (Table 5).
D17S1308 is in the region of the tumor suppressor gene
HIC1. HIC1 has not been previously associated with colon
or breast cancer, but it is an attractive candidate gene.HIC1
is hypermethylated in cancer and is frequently silenced by
epigenetic mechanisms.52 In murine models, Chen et al.53
demonstrated that disruption of HIC1 predisposes to gen-
der-dependent tumors, with males being more likely to de-
velop epithelial cancers and females being more likely to
develop lipoid and mesenchymal cancers, thus making
HIC1 an attractive candidate for gender-dependent cancers
in humans.
More recently, it was shown thatHIC1 binds to the SIRT1
promoter and reduces expression of SIRT1.54 SIRT1 is one
of the SIR2 enzymes collectively called Sirtuins, which
have been linked to cancer and diabetes.54 Both calorie re-
striction and fasting regulate the transcriptional regulation
of SIRT1 through the HIC1:CtBP corepressor complex.54Table 7. Colon/Breast Analysis after Excluding 11 Families Linked to the BRCA2 Locus on Chromosome 13
Group Chromosome (cM)
Concordantly Affected Sib Pairs Discordantly Affected Sib Pairs Concordantly Unaffected Sib Pairs
H-E p ValueAllele Sharing SE p Value Allele Sharing SE p Value Allele Sharing SE p Value
Colon/Breast
13 (26 cM at D13S1493) 0.4780 0.0407 0.7034 0.5672 0.0440 0.9328 0.4416 0.0759 0.7677 0.9574
17 (1 cM at D17S1308) 0.5512 0.0433 0.1223 0.4690 0.0355 0.1941 0.5514 0.0570 0.1824 0.0481
21 (12 cM at D21S1437) 0.5468 0.0488 0.1720 0.4929 0.0348 0.4202 0.4524 0.0858 0.7044 0.3145
21 (57 cM) 0.4865 0.0396 0.6317 0.4297 0.0314 0.0148 0.6184 0.0509 0.0201 0.0147
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Given the context of this candidate gene, examining life-
time dietary habits may be informative in determining
whether ‘‘yo-yo’’ dieting trends and HIC1 expression are
associated with breast and colon cancer. We found no
evidence for linkage to BRCA1 or CHEK2.
The linkagepeak identiﬁed for chromosome7 in the com-
plete analysis has not been previously associatedwithCRC/
colon neoplasia, but the region has been associated with
linkage to bodymass index (BMI) in theOldOrder Amish.55
BMI is a risk factor for CRC and colon neoplasia;56–59
it is speculated that circulating cytokines derived from adi-
pose (fat) tissue may increase the risk for colon neoplasia.
Several less prominent linkage signals overlapped with
regions previously associated with colorectal cancer, in-
cluding BMPR1A, ANXA11 (complete analysis), and EXO1,
MFI2antigen, andGOLGA5 (oligopolyposis phenotype). Sta-
tistically, themost signiﬁcant linkage signalwas observed at
D1S1665 (102 cM, p ¼ 0.00007), with the multiple cancer
phenotype; linkage to chromosome 1 was also observed
with the breast/colon phenotype at 141 cM, (p ¼ 0.0067).
Chromosome 1 is altered in a number of cancer tumors,
with 70%–100% of breast-cancer tumors demonstrating
gains of 1q and 40% of colorectal cancers demonstrating
losses of 1p.47,48 Our observations are consistent with
linked loci (putative and/or protective) in this region.
We veriﬁed the histopathology of the adenomatous
polyps and colon cancers; all other neoplasias were by self
report only, which is a potential limitation of the study.
However, there is high agreement between patient report
and histology in cancer family history.60 In the future, we
hope to both verify these cancers and extend the families.
This CNSS study is the ﬁrst to report a comprehensive
examination of multiple phenotypes derived from the fa-
milial clustering of colon cancer and colon neoplasia.
Both accepted (oligopolyposis) and broad (breast/colon
and multiple cancer) phenotypes were examined, in the
context of a genome-wide linkage scan, thereby not only
expanding our understanding of the phenotypes and of
Figure 4. Mulitple Cancer Peak on
Chromosome 1
Distance is plotted along the x axis, marker
locations are indicated with an ‘‘x,’’ and
both log10 (p value) denoted as pP and
the LOD are plotted on the y axis for refer-
ence purposes. Reference lines at a LOD of
2 and 3 are provided, and significant data
points are labeled with the pP value.
the ethnic groups that demonstrated
linkage to the HMPS/CRAC1 locus
but also identifying fresh candidate
genes/regions, such as chromosome
1q (multiple cancer andbreast/colon),
HIC1 (breast/colon), and chromo-
some 21 (breast/colon). Because we
stratiﬁed the complete set of 194 fam-
ilies intoﬁvephenotypic subgroupsprior toperformingany
linkage analysis and corrected for the equivalence of 4.23
independent traits, this study demonstrated that the inclu-
sion of unaffected individuals and the use of subpheno-
types could increase analytical power in the search for colon
neoplasia susceptibility genes.
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